Citations (47)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Jia Sen Tan, Muhamad Norizwan Bin Jaffar Ali, Bee Koon Gan & Wen Siang Tan. (2023) Next-generation viral nanoparticles for targeted delivery of therapeutics: Fundamentals, methods, biomedical applications, and challenges. Expert Opinion on Drug Delivery 20:7, pages 955-978.
Read now
Read now
Tafere Mulaw Belete. (2021) The Current Status of Gene Therapy for the Treatment of Cancer. Biologics: Targets and Therapy 15, pages 67-77.
Read now
Read now
Moraima Morales-Cruz, Yamixa Delgado, Betzaida Castillo, Cindy M Figueroa, Anna M Molina, Anamaris Torres, Melissa Milián & Kai Griebenow. (2019) Smart Targeting To Improve Cancer Therapeutics. Drug Design, Development and Therapy 13, pages 3753-3772.
Read now
Read now
Stefania Biffi, Rebecca Voltan, Barbara Bortot, Giorgio Zauli & Paola Secchiero. (2019) Actively targeted nanocarriers for drug delivery to cancer cells. Expert Opinion on Drug Delivery 16:5, pages 481-496.
Read now
Read now
Volkmar Weissig, Tracy K Pettinger & Nicole Murdock. (2014) Nanopharmaceuticals (part 1): products on the market. International Journal of Nanomedicine 9, pages 4357-4373.
Read now
Read now
Norio Yamamoto & Hiroyuki Tsuchiya. (2013) Chemotherapy for osteosarcoma – Where does it come from? What is it? Where is it going?. Expert Opinion on Pharmacotherapy 14:16, pages 2183-2193.
Read now
Read now
Articles from other publishers (41)
Lingwan Xie, Yinze Han, Yuanzhi Liu, Yanmei Zhou, Jiao Yu, Albrecht von Brunn & Jian Lei. (2023) Viral vector‐based cancer treatment and current clinical applications. MedComm – Oncology 2:4.
Crossref
Crossref
Howard W. Bruckner, Sant P. Chawla, Nadezhda Omelchenko, Don A. Brigham & Erlinda M. Gordon. (2023) Phase I-II study using DeltaRex-G, a tumor-targeted retrovector encoding a cyclin G1 inhibitor for metastatic carcinoma of breast. Frontiers in Molecular Medicine 3.
Crossref
Crossref
Erlinda M. Gordon & Frederick L. Hall. (2023) The advent of a pan-collagenous CLOVIS POINT for pathotropic targeting and cancer gene therapy, a retrospective. Frontiers in Molecular Medicine 3.
Crossref
Crossref
Xue Bai, Zara Smith, Yuheng Wang, Sam Butterworth & Annalisa Tirella. (2022) Sustained Drug Release from Smart Nanoparticles in Cancer Therapy: A Comprehensive Review. Micromachines 13:10, pages 1623.
Crossref
Crossref
Martiela Vaz de Freitas, Lariane Frâncio, Laura Haleva & Ursula da Silveira Matte. (2022) Protection is not always a good thing: The immune system’s impact on gene therapy. Genetics and Molecular Biology 45:3 suppl 1.
Crossref
Crossref
Mayank Handa, Mangaldeep Dey, Abhas Saxena, Sarwar Beg, Mahfoozur Rahman & Rahul Shukla. 2022. Nanotherapeutics in Cancer Vaccination and Challenges. Nanotherapeutics in Cancer Vaccination and Challenges
77
94
.
Alireza Shahryari, Zahra Nazari, Marie Saghaeian Jazi, Fatemeh Hashemi-Shahraki, Katharina Wißmiller, Weiwei Xu, Ingo Burtscher & Heiko Lickert. 2022. Comprehensive Pharmacology. Comprehensive Pharmacology
326
368
.
Komal Parmar, Jayvadan Patel & Yashwant Pathak. 2022. Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems. Pharmacokinetics and Pharmacodynamics of Nanoparticulate Drug Delivery Systems
261
272
.
Zongmin Zhao, Aaron C. Anselmo & Samir Mitragotri. (2021)
Viral
vector‐based
gene therapies in the clinic
. Bioengineering & Translational Medicine 7:1.
Crossref
Crossref
Hidayati Husainy Hasbullah & Marahaini Musa. (2021) Gene Therapy Targeting p53 and KRAS for Colorectal Cancer Treatment: A Myth or the Way Forward?. International Journal of Molecular Sciences 22:21, pages 11941.
Crossref
Crossref
Cheng Yu, Long Li, Pei Hu, Yan Yang, Wei Wei, Xin Deng, Lu Wang, Franklin R. Tay & Jingzhi Ma. (2021) Recent Advances in Stimulus‐Responsive Nanocarriers for Gene Therapy. Advanced Science 8:14, pages 2100540.
Crossref
Crossref
Erlinda M. Gordon & Frederick L. HallFrederick L. Hall & Erlinda M. Gordon. 2021. Our Journey Beyond Sunset Boulevard - Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on “True” Long-Term Cancer-Free Survival. Our Journey Beyond Sunset Boulevard - Evidence-based Analysis of Tumor-Targeted Gene- and Immuno-Therapies Shine a Critical Spotlight on “True” Long-Term Cancer-Free Survival.
R.J.A. Vibhavari, Gautam Kumar, Vanishree Rao, Sri Pragnya Cheruku & Nitesh Kumar. 2021. Nano-Pharmacokinetics and Theranostics. Nano-Pharmacokinetics and Theranostics
117
152
.
Cui-Cui Ma, Zhen-Ling Wang, Ting Xu, Zhi-Yao He & Yu-Quan Wei. (2020) The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnology Advances 40, pages 107502.
Crossref
Crossref
Suzana Aulic, Domenico Marson, Erik Laurini, Maurizio Fermeglia & Sabrina Pricl. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics
371
404
.
Sonali S. Rohiwal & Arpita Pandey Tiwari. 2020. Nanomedicines for Breast Cancer Theranostics. Nanomedicines for Breast Cancer Theranostics
331
349
.
Derfogail Delcassian & Asha K. Patel. 2020. Bioengineering Innovative Solutions for Cancer. Bioengineering Innovative Solutions for Cancer
197
219
.
Alireza Shahryari, Marie Saghaeian Jazi, Saeed Mohammadi, Hadi Razavi Nikoo, Zahra Nazari, Elaheh Sadat Hosseini, Ingo Burtscher, Seyed Javad Mowla & Heiko Lickert. (2019) Development and Clinical Translation of Approved Gene Therapy Products for Genetic Disorders. Frontiers in Genetics 10.
Crossref
Crossref
Amanda K. Pearce & Rachel K. O’Reilly. (2019) Insights into Active Targeting of Nanoparticles in Drug Delivery: Advances in Clinical Studies and Design Considerations for Cancer Nanomedicine. Bioconjugate Chemistry 30:9, pages 2300-2311.
Crossref
Crossref
Sant P. Chawla, Howard Bruckner, Michael A. Morse, Nupur Assudani, Frederick L. Hall & Erlinda M. Gordon. (2019) A Phase I-II Study Using Rexin-G Tumor-Targeted Retrovector Encoding a Dominant-Negative Cyclin G1 Inhibitor for Advanced Pancreatic Cancer. Molecular Therapy - Oncolytics 12, pages 56-67.
Crossref
Crossref
Sara Nidal Abed, Pran Kishore Deb, Hiba Salim Surchi, Sarah Falah Kokaz, Saadh Mohamed Jamal, Shantanu Bandopadhyay & Rakesh K. Tekade. 2019. Basic Fundamentals of Drug Delivery. Basic Fundamentals of Drug Delivery
685
731
.
Cornelia Vasile. 2019. Polymeric Nanomaterials in Nanotherapeutics. Polymeric Nanomaterials in Nanotherapeutics
1
66
.
Nazish Tabassum, Vinod Verma, Manoj Kumar, Ashok Kumar & Birbal Singh. (2018) Nanomedicine in cancer stem cell therapy: from fringe to forefront. Cell and Tissue Research 374:3, pages 427-438.
Crossref
Crossref
Pramila Khandel, Ravi Kumar Yadaw, Deepak Kumar Soni, Leeladhar Kanwar & Sushil Kumar Shahi. (2018) Biogenesis of metal nanoparticles and their pharmacological applications: present status and application prospects. Journal of Nanostructure in Chemistry 8:3, pages 217-254.
Crossref
Crossref
Erlinda Gordon, Joshua Ravicz, Seiya Liu, Sant Chawla & Frederick Hall. (2018) Cell cycle checkpoint control: The cyclin G1/Mdm2/p53 axis emerges as a strategic target for broad‑spectrum cancer gene therapy - A review of molecular mechanisms for oncologists. Molecular and Clinical Oncology.
Crossref
Crossref
Tu-Hsueh Yeh, Han-Fang Liu, Yu-Wen Li, Chin-Song Lu, Hung-Yu Shih, Ching-Chi Chiu, Sheng-Jia Lin, Yin-Cheng Huang & Yi-Chuan Cheng. (2018) C9orf72 is essential for neurodevelopment and motility mediated by Cyclin G1. Experimental Neurology 304, pages 114-124.
Crossref
Crossref
Seth Kim, Noah Federman, Erlinda M. Gordon, Frederick L. Hall & Sant P. Chawla. (2017) Rexin-G®, a tumor-targeted retrovector for malignant peripheral nerve sheath tumor: A case report. Molecular and Clinical Oncology 6:6, pages 861-865.
Crossref
Crossref
Sofia M. Saraiva, Vanessa Castro-López, Covadonga Pañeda & María José Alonso. (2017) Synthetic nanocarriers for the delivery of polynucleotides to the eye. European Journal of Pharmaceutical Sciences 103, pages 5-18.
Crossref
Crossref
Ann-Marie Ako-Adounvo, Beatriz Marabesi, Rayssa Costa Lemos, Ayuk Patricia & Pradeep K. Karla. 2017. Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices. Emerging Nanotechnologies for Diagnostics, Drug Delivery and Medical Devices
375
392
.
Daniel Bobo, Kye J. Robinson, Jiaul Islam, Kristofer J. Thurecht & Simon R. Corrie. (2016) Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date. Pharmaceutical Research 33:10, pages 2373-2387.
Crossref
Crossref
Johannes C.M. van der Loo & J. Fraser Wright. (2016) Progress and challenges in viral vector manufacturing. Human Molecular Genetics 25:R1, pages R42-R52.
Crossref
Crossref
Dongsheng Duan. (2016) Dystrophin Gene Replacement and Gene Repair Therapy for Duchenne Muscular Dystrophy in 2016: An Interview. Human Gene Therapy Clinical Development 27:1, pages 9-18.
Crossref
Crossref
Erlinda Gordon. (2016) Targeting Monoclonal Antibodies to the Tumor Microenvironment for Cancer Therapy/Immunotherapy. Journal of Immunology and Serum Biology 2:1, pages 1-7.
Crossref
Crossref
Roy van der Meel, Laurens J. C. Vehmeijer, Robbert Jan Kok, Gert Storm & Ethlinn V. B. van Gaal. 2016. Intracellular Delivery III. Intracellular Delivery III
163
200
.
Gregory Benedetto, C. Greer Vestal & Christine Richardson. (2015) Aptamer-Functionalized Nanoparticles as “Smart Bombs”: The Unrealized Potential for Personalized Medicine and Targeted Cancer Treatment. Targeted Oncology 10:4, pages 467-485.
Crossref
Crossref
James B DelehantyJoyce C Breger, Kelly Boeneman Gemmill, Michael H Stewart & Igor L Medintz. (2013) Controlling the actuation of therapeutic nanomaterials: enabling nanoparticle-mediated drug delivery. Therapeutic Delivery 4:11, pages 1411-1429.
Crossref
Crossref
Roy van der Meel, Laurens J.C. Vehmeijer, Robbert J. Kok, Gert Storm & Ethlinn V.B. van Gaal. (2013) Ligand-targeted particulate nanomedicines undergoing clinical evaluation: Current status. Advanced Drug Delivery Reviews 65:10, pages 1284-1298.
Crossref
Crossref
Ruibing Wang, Paul S. Billone & Wayne M. Mullett. (2013) Nanomedicine in Action: An Overview of Cancer Nanomedicine on the Market and in Clinical Trials. Journal of Nanomaterials 2013, pages 1-12.
Crossref
Crossref
Alexander Wei, Jonathan G. Mehtala & Anil K. Patri. (2012) Challenges and opportunities in the advancement of nanomedicines. Journal of Controlled Release 164:2, pages 236-246.
Crossref
Crossref
Thomas Wirth. (2011) A short perspective on gene therapy: Clinical experience on gene therapy of gliomablastoma multiforme. World Journal of Experimental Medicine 1:1, pages 10.
Crossref
Crossref
Long Xu & Thomas Anchordoquy. (2011) CLINICAL TRIALS AND TRANSLATIONAL MEDICINE COMMENTARY: Drug Delivery Trends in Clinical Trials and Translational Medicine: Challenges and Opportunities in the Delivery of Nucleic Acid-Based Therapeutics. Journal of Pharmaceutical Sciences 100:1, pages 38-52.
Crossref
Crossref